Oruka Therapeutics, Inc.

ORKA

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
SEC CIK: 0000907654

SEC filings (opens in a new tab)

In the last 90 days, Oruka Therapeutics, Inc. insiders filed 0 open-market purchases and 17 sales; 256 institutions reported holding it in 13F filings for Q2 2026, worth $7.05B in total; Viking Global Investors is the only superinvestor holding it.

Key figures

Market capClose on Nov 9, 2026: $6.92B
Insider buysOpen market, last 90 days: 0
Insider sellsLast 90 days, $24.4M in total: 17
13F holdersQ2 2026, +73 vs. previous quarter: 256
13F valueReported value at the end of Q2 2026: $7.05B
Superinvestors holdingAt the end of Q2 2026: 1

Price chart

Chart by TradingView (opens in a new tab)

Financials

See financial statements

From SEC filings, in USD.

Revenue, FY2025: –; No comparable prior period
Net income, FY2025: -$105.4M; No comparable prior period
Free cash flow, FY2025: -$88.4M; No comparable prior period
Revenue, Q3 FY2026: –; No comparable prior period

Short interest

See short data

From FINRA, settlement date Oct 15, 2026.

Short interest: 6.11M; Shares sold short
Change: −1.67M; −21.4% vs. previous
Days to cover: 7.26; At average daily volume

Superinvestors holding ORKA, Q2 2026

Go to the superinvestors tab

1 superinvestor reports holding Oruka Therapeutics, Inc. on Form 13F. Percentages are the stock's share of each portfolio.

Viking Global Investors

Andreas Halvorsen

0.4%

Oruka Therapeutics, Inc.'s share of the portfolio

Shares: 1,503,478
Value: $143.1M

Latest insider trades

See all insider trades

Open-market purchases and sales by Oruka Therapeutics, Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)	Trade date	Filing delay	Insider	Transaction	Shares	Avg price	Value	Holding change	Flags
Nov 2, 2026 (view filing)5:46 PM ET	Nov 2	Same day	Klein Lawrence OttoChief Executive Officer	SSale	−25.0K	$95.60	−$2.39M	−2.6%923.1K after	5 lots10b5-1
Oct 20, 2026 (view filing)8:42 PM ET	Oct 20	Same day	Quinlan Paul TGeneral Counsel	SSale	−9.00K	$78.53	−$706.7K	−23.1%30.0K after	5 lots10b5-1
Oct 15, 2026 (view filing)6:15 PM ET	Oct 15	Same day	Goncalves JoanaChief Medical Officer	SSale	−7.00K	$74.81	−$523.6K	−18.1%31.8K after	5 lots10b5-1
Oct 13, 2026 (view filing)4:34 PM ET	Oct 12	1 day	Agarwal ArjunSenior Vice President, Finance	SSale	−10.0K	$80.60	−$805.9K	−41.3%14.2K after	4 lots10b5-1
Oct 2, 2026 (view filing)7:54 PM ET	Oct 1	1 day	Klein Lawrence OttoChief Executive Officer	SSale	−25.0K	$83.62	−$2.09M	−2.6%923.1K after	3 lots10b5-1
Sep 21, 2026 (view filing)5:38 PM ET	Sep 21	Same day	Agarwal ArjunSenior Vice President, Finance	SSale	−533	$95.75	−$51.0K	−3.6%14.2K after	10b5-1
Sep 21, 2026 (view filing)4:57 PM ET	Sep 21	Same day	Quinlan Paul TGeneral Counsel	SSale	−10.0K	$93.64	−$936.4K	−25.0%30.0K after	4 lots10b5-1
Sep 15, 2026 (view filing)7:18 PM ET	Sep 15	Same day	Goncalves JoanaChief Medical Officer	SSale	−7.95K	$92.38	−$734.1K	−20.0%31.8K after	5 lots10b5-1
Sep 15, 2026 (view filing)7:17 PM ET	Sep 11-15	4 days	Agarwal ArjunSenior Vice President, Finance	SSale	−10.0K	$92.43	−$926.0K	−40.4%14.8K after	5 lots10b5-1
Sep 15, 2026 (view filing)7:15 PM ET	Sep 15	Same day	Klein Lawrence OttoChief Executive Officer	SSale	−2.45K	$95.71	−$234.7K	−0.3%923.1K after

Top 10 13F holders, Q2 2026

See all 256 holders

The largest institutional positions in Oruka Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.

Institutions holding ORKA in Q2 2026
Institution	Shares	Value	% of portfolio	Change in shares	Action
FMR LLC	9,057,645	$862.0M	0.04%	+1,626,242+21.9%	Added
BlackRock, Inc.	4,990,181	$474.9M	0.01%	+1,463,094+41.5%	Added
VR Adviser, LLC	4,148,428	$394.8M	11.97%	00.0%	Unchanged
Fairmount Funds Management LLC	3,705,262	$352.6M	23.31%	00.0%	Unchanged
Capital World Investors	3,401,639	$323.7M	0.04%	+3,401,639	New
RTW Investments, LP	3,139,030	$298.7M	2.55%	+1,080,882+52.5%	Added
State Street Corp	2,673,090	$254.4M	0.01%	+1,059,629+65.7%	Added
Vanguard Capital Management LLC	2,360,971	$224.7M	0.00%	+501,340+27.0%	Added
Paradigm Biocapital Advisors LP	2,144,526	$204.1M	3.82%	−175,790−7.6%	Reduced
Deep Track Capital, LP	1,926,000	$183.3M	2.70%	−108,203−5.3%	Reduced

Holders of 5% or more of ORKA

See all 5 holders and filings

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Oruka Therapeutics, Inc..

Largest holders of ORKA from 13D and 13G filings
Holder	Latest form	Stake	Change	First filed	Latest filing	Filing
Fairmount Funds Management LLC	13D/A	19.50%14.6M shares	−0.49 ppfrom 19.99%	Sep 6, 20247 filings	Jul 1, 2026	SEC
Venrock Healthcare Capital Partners III, L.P.	13G/A	7.40%4.56M shares	−2.50 ppfrom 9.90%	Apr 29, 20245 filings	Aug 14, 2026	SEC
BlackRock, Inc.	13G	6.60%3.18M shares	+2.10 ppfrom 4.50%	Jul 17, 20253 filings	Jan 21, 2026	SEC
Capital World Investors	13G	5.60%3.40M shares	New	Aug 12, 20261 filing	Aug 12, 2026	SEC
RTW Investments, LP	13G	5.20%3.14M shares	+0.90 ppfrom 4.30%	May 15, 20253 filings	Aug 14, 2026	SEC